Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, AM Frezza, O Venditti, M Imperatori, Gaia Schiavon, G Bronte, G Cicero, F Recine, E Maiello, S Cascinu, AP Russo, A Falcone, G Tonini

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19 partial responses (48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients and progression in four patients (10.2%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and du Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.
Original languageEnglish
Pages (from-to)2313-2318
Number of pages6
JournalAnnals of Oncology
Volume23
Issue number9
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?'. Together they form a unique fingerprint.

Cite this